连续监测尿CC基序趋化因子配体14与持续性重度急性肾损伤风险
本研究为回顾性观察研究,数据来自Ruby和Sapphire两项跨国ICU研究,纳入早期2-3期AKI危重患者,按KDIGO标准诊断后每12小时连续检测3次uCCL14,依据预设经验证界值分为低(≤1.3 ng/mL)、中(>1.3至≤13 ng/mL)、高(>13 ng/mL)三级。417例完成3次检测的患者中75例发生持续性重度AKI;66%患者前24小时uCCL14分级不变,分级下降与持续性重度AKI风险降低相关(OR 0.20;95%CI 0.08-0.45;P<0.001),分级上升与风险升高相关(OR 4.04;95%CI 1.75-9.46;P=0.001)。作者认为连续uCCL14检测可能发现肾脏病理进展或缓解,并帮助细化AKI预后。
要点
- 对早期2-3期AKI危重患者,诊断后每12小时连续检测uCCL14共3次,依据预设经验证界值分为低(≤1.3 ng/mL)、中(>1.3至≤13 ng/mL)、高(>13 ng/mL)三级。
- 417例完成3次检测的患者中75例发生持续性重度AKI(定义为连续72小时3期AKI、死亡或72小时内接受透析)。
- 初始uCCL14分级与主要终点强相关,66%患者前24小时uCCL14分级不变。
- 校正基线分级后,uCCL14分级下降与持续性重度AKI风险降低相关(OR 0.20;95%CI 0.08-0.45;P<0.001),分级上升与风险升高相关(OR 4.04;95%CI 1.75-9.46;P=0.001)。
- 作者认为连续uCCL14检测可能发现肾脏病理进展或缓解,并帮助细化AKI预后。
适用人群与场景
- 数据来自Ruby和Sapphire两项跨国ICU研究,纳入早期2-3期AKI危重患者。
- 分析对象为完成3次连续uCCL14检测(每12小时一次)的417例患者。
诊断标准与关键阈值
- AKI诊断依据Kidney Disease Improving Global Outcomes(KDIGO)标准,为2-3期。
- uCCL14依据预设经验证界值分级:低(≤1.3 ng/mL)、中(>1.3至≤13 ng/mL)、高(>13 ng/mL)。
- 持续性重度AKI定义:连续72小时3期AKI、死亡或72小时内接受透析。
处置流程与药物剂量
- uCCL14采用NEPHROCLEAR uCCL14 Test在Astute 140 Meter(Astute Medical, San Diego, CA)上检测。
- KDIGO标准诊断2-3期AKI后,每12小时检测一次uCCL14,连续3次。
研究设计与关键结果
- 研究类型:回顾性观察研究,数据来自Ruby和Sapphire两项跨国ICU研究;人群为早期2-3期AKI危重患者;无干预。
- 417例完成3次连续uCCL14检测的患者中,75例发生持续性重度AKI。
- 初始uCCL14分级与主要终点强相关,66%患者前24小时uCCL14分级不变。
- 校正基线分级后,uCCL14分级下降与持续性重度AKI风险降低相关(OR 0.20;95%CI 0.08-0.45;P<0.001)。
- 校正基线分级后,uCCL14分级上升与持续性重度AKI风险升高相关(OR 4.04;95%CI 1.75-9.46;P=0.001)。
证据类型、等级与局限
- 证据类型:回顾性观察研究,数据来自Ruby和Sapphire两项跨国ICU研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,连续uCCL14检测可能发现肾脏病理进展或缓解,并帮助细化AKI预后。
- 对早期2-3期AKI危重患者,连续3次(每12小时)uCCL14分级变化与持续性重度AKI风险改变相关;约三分之一患者分级在3次检测中发生变化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To assess the added prognostic value of serial monitoring of urinary C-C motif chemokine ligand 14 (uCCL14) over that of single measurements, which have been shown to be prognostic for development of persistent severe acute kidney injury (AKI) in critically ill patients.
DESIGN: Retrospective observational study.
SETTING: Data derived from two multinational ICU studies (Ruby and Sapphire).
PATIENTS: Critically ill patients with early stage 2-3 AKI.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We analyzed three consecutive uCCL14 measurements at 12-hour intervals after diagnosis of stage 2-3 AKI by Kidney Disease Improving Global Outcomes criteria. Primary outcome was persistent severe AKI, defined as 72 consecutive hours of stage 3 AKI, death, or receipt of dialysis prior to 72 hours. uCCL14 was measured using the NEPHROCLEAR uCCL14 Test on the Astute 140 Meter (Astute Medical, San Diego, CA). Based on predefined, validated cutoffs, we categorized uCCL14 as: low (≤ 1.3 ng/mL), medium (> 1.3 to ≤ 13 ng/mL), or high (> 13 ng/mL). Seventy-five of 417 patients with three consecutive uCCL14 measurements developed persistent severe AKI. Initial uCCL14 category strongly correlated with primary endpoint and, in most cases (66%), uCCL14 category was unchanged over the first 24 hours. Compared with no change and accounting for baseline category, decrease in category was associated with decreased odds of persistent severe AKI (odds ratio [OR], 0.20; 95% CI, 0.08-0.45; p < 0.001) and an increase in category with increased odds (OR, 4.04; 95% CI, 1.75-9.46; p = 0.001).
CONCLUSIONS: In one-third of patients with moderate to severe AKI uCCL14 risk category altered over three serial measurements and such changes were associated with altered risk for persistent severe AKI. Serial CCL-14 measurement may detect progression or resolution of underlying kidney pathology and help refine AKI prognosis.
参考来源
- Prowle JR, Artigas A, Bagshaw SM, et al. Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury. Crit Care Explor. 2023. PMID: 36875557. doi:10.1097/CCE.0000000000000870
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。